TxCell acquires the exclusive worldwide rights on a new population of regulatory T cells from Inserm Transfert.
Valbonne and Nantes, France, 8 December 2016 – TxCell SA (FR0010127662 – TXCL), a biotechnology company which is developing innovative personalised cell immunotherapies from regulatory T cells (Treg) to treat chronic inflammatory and autoimmune diseases and Inserm Transfert on behalf of Inserm, the Nantes University and Nantes University Hospital, announced today the signature of an exclusive worldwide licence agreement.
Tregs CD8+ are non-cytotoxic agents which have a unique and potent immunosuppressant mechanism of action.
It will therefore be possible to incorporate Tregs CD8+ into the TxCell platform to offer a different complementary approach to inflammatory and autoimmune diseases.
According to the terms of the agreement, TxCell has acquired an exclusive worldwide licence relating to two families of patents submitted by the Centre for Transplantation and Immunology Research (CRTI). CRTI is the centre of excellence in transplantation and immunology. This is a research unit (UMR 1064) affiliated to the French National Institute for Health and Medical Research (Inserm) and to the Nantes University.